|

Lung Cancer Clinical Trials in Austin, TX

52 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1<1 mi
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1<1 mi
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerPhase 2<1 mi
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerPhase 2<1 mi
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPhase 1<1 mi
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3<1 mi
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung CancerPhase 2<1 mi
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease—<1 mi
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2<1 mi
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCPhase 2<1 mi
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3<1 mi
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3<1 mi
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Phase 2<1 mi
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerPhase 1<1 mi
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)Phase 3<1 mi
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1<1 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3<1 mi
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASPhase 3<1 mi
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2<1 mi
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Phase 2<1 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsPhase 3<1 mi
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsPhase 1<1 mi
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1<1 mi
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3<1 mi
Study of XB010 in Subjects With Solid TumorsPhase 1<1 mi
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerPhase 1/2<1 mi
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3<1 mi
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPPhase 1/2<1 mi
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsPhase 1/2<1 mi
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsPhase 3<1 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3<1 mi
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)Phase 3<1 mi
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/2<1 mi
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/2<1 mi
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsPhase 1<1 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabPhase 1<1 mi
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Phase 3<1 mi
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Phase 1/2<1 mi
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).Phase 3<1 mi
Study of Novel Treatment Combinations in Patients With Lung CancerPhase 2<1 mi
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasPhase 1<1 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2<1 mi
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/3<1 mi
Sample Collection for Ongoing Research and Product Evaluation Study—<1 mi
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsPhase 1/2<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 1<1 mi
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 117 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPhase 317 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Phase 317 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLCPhase 317 mi
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerPhase 345 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.